Five-Year Survival Outcomes With Atezolizumab After Chemotherapy in Resected Stage IB-IIIA Non-Small Cell Lung Cancer (IMpower010): An Open-Label, Randomized, Phase III Trial [0.03%]
围手术期化疗后的非小细胞肺癌患者使用阿特朱单抗(IMpower010):一项开放性、随机、III期试验的五年生存结果
Enriqueta Felip,Nasser Altorki,Caicun Zhou et al.
Enriqueta Felip et al.
IMpower010 (ClinicalTrials.gov identifier: NCT02486718) previously showed that atezolizumab improved disease-free survival (DFS) versus best supportive care (BSC) after adjuvant chemotherapy in patients with resected non-small cell lung can...
Survival Benefit of Palliative Oophorectomy for Patients With Ovarian Metastasis From Baseline Metastatic Gastric Adenocarcinoma [0.03%]
基线转移性胃腺癌伴卵巢转移患者的姑息性卵巢切除术生存获益
Matheus Sewastjanow-Silva,Lianchun Xiao,Ahmed Abdelhakeem et al.
Matheus Sewastjanow-Silva et al.
Purpose: To compare overall survival (OS) in patients with baseline metastatic gastric adenocarcinoma (GA) with and without ovarian metastasis (OM). Furthermore, within the group that had ovarian metastases, we aimed to a...
BMT-CARE App: A Randomized Controlled Trial of a Psychosocial Digital Application for Caregivers of Patients Undergoing Hematopoietic Stem-Cell Transplantation [0.03%]
BMT-CARE应用程序：造血干细胞移植患者照顾者的心理社会数字应用随机对照试验
Jamie M Jacobs,Lara Traeger,Madison Freese et al.
Jamie M Jacobs et al.
Purpose: Family and friend caregivers of patients undergoing hematopoietic stem-cell transplantation (HSCT) struggle with immense caregiving burden, leading to substantial quality of life (QOL) impairments and psychologic...
Long-Term Dynamic Financial Impacts Among Adolescents and Young Adults With Cancer: A Longitudinal Matched-Cohort Study [0.03%]
癌症青少年和年轻成人长期的动态经济影响：纵向队列研究
Giancarlo Di Giuseppe,Arif Jetha,Petros Pechlivanoglou et al.
Giancarlo Di Giuseppe et al.
Purpose: Surviving cancer has significant financial implications for adolescents and young adults (AYAs). It is unclear how cancer affects AYA income over time compared with the general population, and how this differs by...
Mantle Cell Lymphoma: Optimal Treatment With Bruton Tyrosine Kinase-Targeted Approaches [0.03%]
布鲁顿酪氨酸激酶靶向疗法优化治疗套细胞淋巴瘤
Toby A Eyre,Chan Y Cheah,Clémentine Sarkozy et al.
Toby A Eyre et al.
Mantle cell lymphoma (MCL) represents a relatively uncommon, heterogeneous lymphoma associated with limited overall survival. Targeting of the B-cell receptor pathway in relapsed disease with covalent Bruton tyrosine kinase (cBTK) inhibitio...
Randomized Phase II Study of Concurrent Versus Sequential Pembrolizumab in Combination With Chemoradiation in Locally Advanced Head and Neck Cancer [0.03%]
帕博利珠单抗联合同期与序贯放化疗治疗局部晚期头颈部肿瘤的二期随机临床试验
Dan P Zandberg,Lazar Vujanovic,David A Clump et al.
Dan P Zandberg et al.
Purpose: The optimal timing of pembrolizumab with chemoradiation (CRT) in locally advanced (LA) head and neck squamous cell carcinoma (HNSCC) is unknown. ...
Randomized Phase III Trial of Ramucirumab Beyond Progression Plus Irinotecan in Patients With Ramucirumab-Refractory Advanced Gastric Cancer: RINDBeRG Trial [0.03%]
雷莫卢单抗联合伊立替康治疗晚期胃癌RINDBeRG 随机III期临床研究
Daisuke Sakai,Shigenori Kadowaki,Ryohei Kawabata et al.
Daisuke Sakai et al.
Purpose: Continuous use of antiangiogenic agents has demonstrated survival benefits in various cancers. This trial aimed to compare the efficacy and safety of ramucirumab plus irinotecan with irinotecan monotherapy as a t...
Cancer Surveillance in the United States in Jeopardy: Leveraging 21st Century Technology to Enhance Public Health [0.03%]
美国癌症监测面临危机：利用21世纪技术提升公共卫生水平
Lawrence N Shulman,Cathy J Bradley,Robert A Winn et al.
Lawrence N Shulman et al.
Updated Overall Survival and Long-Term Safety With Ripretinib Versus Sunitinib in Patients With GI Stromal Tumor: Final Overall Survival Analysis From INTRIGUE [0.03%]
芦可替尼与索拉非尼治疗胃肠道间质瘤患者的总生存期和长期安全性：INTRIGUE最终分析结果
Michael C Heinrich,Jean-Yves Blay,Hans Gelderblom et al.
Michael C Heinrich et al.
In the INTRIGUE phase III trial (ClinicalTrials.gov identifier: NCT03673501), adult patients with advanced gastrointestinal stromal tumor previously treated with imatinib were randomly assigned 1:1 to ripretinib 150 mg once daily or sunitin...